Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection of Colonic Abnormalities
This study is enrolling participants by invitation only.
Sponsored by: Given Imaging Ltd.
Information provided by: Given Imaging Ltd.
ClinicalTrials.gov Identifier: NCT00604422
  Purpose

To evaluate the ability of the PillCam Colon Capsule Endoscope to detect colonic abnormalities


Condition
Colonic Disease
Ulcerative Colitis

Genetics Home Reference related topics: Crohn disease
MedlinePlus related topics: Colonic Diseases Endoscopy Ulcerative Colitis
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection of Colonic Abnormalities

Further study details as provided by Given Imaging Ltd.:

Primary Outcome Measures:
  • Accuracy parameters (sensitivity, specificity, NPV, PPV) of PCCE compared to standard colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number, type and severity of adverse events with both PCCE and standard colonoscopy [ Time Frame: Within 7 days ] [ Designated as safety issue: No ]
  • Number of findings detected by PCCE compared to number of findings detected by standard colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Colon cleansing level score for both PCCE and standard colonoscopy. [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Percentage of excreted colon capsules [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • PCCE transit time per anatomic location (stomach, small bowel, colon) [ Time Frame: within 7 days ] [ Designated as safety issue: No ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Enrollment: 40
Study Start Date: April 2007
Estimated Study Completion Date: April 2008
Groups/Cohorts
A
Subjects that are indicated for standard colonoscopy due to suspected or known colonic disease

Detailed Description:

The evaluation of subjects with suspected colonic disease includes endoscopic imaging by colonoscopy and radiologic imaging such as air-contrast barium enema, abdominal/pelvic CT, or virtual colonoscopy. The Given® Diagnostic System offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the Given® Diagnostic System include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the Given® Diagnostic System may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon and comply with colorectal cancer screening recommendations.

The PillCam™ SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 300,000 people worldwide and is well accepted by patients and physicians as well as the processional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. This is expected to improve the capability of the Given® Diagnostic System to detect colonic pathologies and to serve as a diagnostic and screening tool for colonic disease. Further details of the PillCam™ Colon Capsule Endoscope (PCCE) can be found in the device description section.

This study is designed to compare capsule colonoscopy and colonoscopy procedures in detecting colon abnormalities.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Subjects that are indicated for standard colonoscopy due to suspected or known colonic disease.

The study population will consist of subjects who fulfill all the inclusion criteria and none of the exclusion criteria.

Criteria

Inclusion Criteria:

  • Subjects 18-70
  • Subject was referred to colonoscopy due to one or more of the following clinical symptoms: rectal bleeding, hematochezia, melena, positive FOBT, localized abdominal pain altered bowel habits
  • Subject was referred to colonoscopy due to abnormal Ba enema or CT colonography.
  • Suspected or known Ulcerative colitis patients

Exclusion Criteria:

  • Subject has dysphagia
  • Subject has congestive heart failure
  • Subject who can not tolerate bowel preparation
  • Poor bowel preparation
  • Subject has renal insufficiency
  • Subject is known or is suspected to suffer from intestinal obstruction.
  • Subject has a cardiac pacemaker or other implanted electro medical devices.
  • Subject is pregnant
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Subject suffers from life threatening conditions
  • Subject is currently participating in another clinical study
  • Subject has constipation (less than 3 bowel movements/week)
  • Subject has known slow gastric emptying time
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00604422

Locations
Hong Kong
Chinese university of Hong Kong, Princes of Walses Hospital
Hong Kong, Hong Kong
Sponsors and Collaborators
Given Imaging Ltd.
Investigators
Principal Investigator: Josef Sung, Prof. Chinese University of Hong Kong
  More Information

Responsible Party: Given Imaging Ltd. ( Yael Koren - Corp. Director Clinical Affairs )
Study ID Numbers: MA-107
Study First Received: January 24, 2008
Last Updated: January 29, 2008
ClinicalTrials.gov Identifier: NCT00604422  
Health Authority: Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee

Keywords provided by Given Imaging Ltd.:
Colonic disease
Ulcerative colitis
suspected or known colonic disease

Study placed in the following topic categories:
Digestive System Diseases
Gastrointestinal Diseases
Ulcer
Colonic Diseases
Inflammatory Bowel Diseases
Colitis, Ulcerative
Intestinal Diseases
Gastroenteritis
Congenital Abnormalities
Colitis

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on January 14, 2009